JP2012508215A5 - - Google Patents

Download PDF

Info

Publication number
JP2012508215A5
JP2012508215A5 JP2011535129A JP2011535129A JP2012508215A5 JP 2012508215 A5 JP2012508215 A5 JP 2012508215A5 JP 2011535129 A JP2011535129 A JP 2011535129A JP 2011535129 A JP2011535129 A JP 2011535129A JP 2012508215 A5 JP2012508215 A5 JP 2012508215A5
Authority
JP
Japan
Prior art keywords
salt
salt according
optionally
degrees
ray powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011535129A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012508215A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2009/064889 external-priority patent/WO2010055027A2/en
Publication of JP2012508215A publication Critical patent/JP2012508215A/ja
Publication of JP2012508215A5 publication Critical patent/JP2012508215A5/ja
Withdrawn legal-status Critical Current

Links

JP2011535129A 2008-11-11 2009-11-10 有機化合物 Withdrawn JP2012508215A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08168862 2008-11-11
EP08168862.4 2008-11-11
PCT/EP2009/064889 WO2010055027A2 (en) 2008-11-11 2009-11-10 Organic compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015089480A Division JP2015178503A (ja) 2008-11-11 2015-04-24 有機化合物

Publications (2)

Publication Number Publication Date
JP2012508215A JP2012508215A (ja) 2012-04-05
JP2012508215A5 true JP2012508215A5 (cg-RX-API-DMAC10.html) 2012-12-20

Family

ID=42062355

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011535129A Withdrawn JP2012508215A (ja) 2008-11-11 2009-11-10 有機化合物
JP2015089480A Withdrawn JP2015178503A (ja) 2008-11-11 2015-04-24 有機化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015089480A Withdrawn JP2015178503A (ja) 2008-11-11 2015-04-24 有機化合物

Country Status (20)

Country Link
US (2) US8680146B2 (cg-RX-API-DMAC10.html)
EP (1) EP2358660A2 (cg-RX-API-DMAC10.html)
JP (2) JP2012508215A (cg-RX-API-DMAC10.html)
KR (1) KR20110086142A (cg-RX-API-DMAC10.html)
CN (2) CN105198760A (cg-RX-API-DMAC10.html)
AU (1) AU2009315735B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0921533A2 (cg-RX-API-DMAC10.html)
CA (1) CA2741974A1 (cg-RX-API-DMAC10.html)
CL (1) CL2011001041A1 (cg-RX-API-DMAC10.html)
CO (1) CO6382154A2 (cg-RX-API-DMAC10.html)
EC (1) ECSP11011121A (cg-RX-API-DMAC10.html)
IL (1) IL212073A0 (cg-RX-API-DMAC10.html)
MA (1) MA32877B1 (cg-RX-API-DMAC10.html)
MX (1) MX2011004924A (cg-RX-API-DMAC10.html)
NZ (1) NZ591999A (cg-RX-API-DMAC10.html)
PE (1) PE20120012A1 (cg-RX-API-DMAC10.html)
RU (1) RU2543621C2 (cg-RX-API-DMAC10.html)
TN (1) TN2011000187A1 (cg-RX-API-DMAC10.html)
WO (1) WO2010055027A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA201102272B (cg-RX-API-DMAC10.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2325171B1 (en) 2005-05-26 2013-10-09 Aldexa Therapeutics, Inc. Quinoline derivatives for treating retinal diseases
AU2009315735B2 (en) * 2008-11-11 2013-01-10 Novartis Ag Salts of fingolimod
WO2011009634A2 (en) * 2009-07-24 2011-01-27 Ratiopharm Gmbh Process for producing fingolimod salts
US9814701B2 (en) 2009-12-11 2017-11-14 Aldeyra Therapeutics, Inc. Compositions and methods for the treatment of macular degeneration
PL2632889T3 (pl) 2010-10-28 2019-04-30 Mapi Pharma Ltd Związki pośrednie i sposób wytwarzania fingolimodu
WO2012071524A1 (en) 2010-11-24 2012-05-31 Ratiopharm Gmbh Arylsulfonate salts of fingolimod and processes for preparation thereof
AR085749A1 (es) 2011-04-01 2013-10-23 Novartis Ag Formulaciones
EP2505589A1 (en) 2011-04-01 2012-10-03 Johann Wolfgang Goethe-Universität Frankfurt am Main Novel sphingolipid heterocyclic compounds as modulators of sphingolipid signaling and uses thereof
CN102887829B (zh) * 2012-09-05 2014-07-02 中国科学院上海药物研究所 芬戈莫德粘酸盐及其晶体的制备方法和用途
CN105120866B (zh) 2013-01-23 2020-02-14 奥尔德拉医疗公司 与毒性醛相关的疾病和治疗
RU2663833C2 (ru) 2013-03-05 2018-08-10 Биокон Лимитед Способ получения соединений 2-амино-1,3-пропандиола и их солей
WO2015053878A1 (en) 2013-10-11 2015-04-16 Teikoku Pharma Usa, Inc. Topical sphingosine-1-phosphate receptor agonist formulations and methods of using the same
WO2015053879A1 (en) 2013-10-11 2015-04-16 Teikoku Pharma Usa, Inc. Sphingosine-1-phosphate receptor agonist iontophoretic devices and methods of using the same
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
CN107530301A (zh) * 2015-01-20 2018-01-02 汉达医药有限责任公司 稳定的固体芬戈莫德剂型
CN118724806A (zh) 2015-08-21 2024-10-01 奥尔德拉医疗公司 氘化化合物和其用途
EP3454858A4 (en) 2016-05-09 2020-01-15 Aldeyra Therapeutics, Inc. COMBINATION TREATMENT OF FLAMMABLE CONDITIONS AND DISEASES OF THE EYE
RU2732572C2 (ru) 2016-05-31 2020-09-21 Тайхо Фармасьютикал Ко., Лтд. Сульфонамидное соединение или его соль
RU2627691C1 (ru) * 2016-07-06 2017-08-10 Олег Ростиславович Михайлов Кристаллическая η-модификация 2-амино-2-(2-(4-октилфенил)этил)пропан-1,3-диол гидрохлорида, способ её получения и фармацевтическая композиция на её основе
US11040039B2 (en) 2017-10-10 2021-06-22 Aldeyra Therapeutics, Inc. Treatment of inflammatory disorders
MY201832A (en) 2017-11-29 2024-03-19 Taiho Pharmaceutical Co Ltd Sulfonamide compounds and use thereof
CA3103153A1 (en) * 2018-06-29 2020-01-02 Forma Therapeutics, Inc. Salts of (s)-(5-cyclobutoxy-2-methyl-6-(1-(piperidin-4-yl)-1h-pyrazol-4-yl)-3,4-dihydroquinolin-1(2h)-yl)(cyclopropyl)methanone and solid forms thereof
JP2021533154A (ja) * 2018-08-06 2021-12-02 アルデイラ セラピューティクス, インコーポレイテッド 多形化合物およびその使用
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
WO2020223685A1 (en) 2019-05-02 2020-11-05 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
KR20220093330A (ko) 2019-10-31 2022-07-05 이도르시아 파마슈티컬스 리미티드 Cxcr7 안타고니스트와 s1p1 수용체 조절인자의 조합
JP2023526016A (ja) 2020-05-13 2023-06-20 アルデイラ セラピューティクス, インコーポレイテッド 医薬製剤およびその使用
CN115477590B (zh) * 2021-05-31 2023-12-12 上海云晟研新生物科技有限公司 芬戈莫德药用盐、制备方法、含其的药物组合物及应用
EP4212156A1 (en) 2022-01-13 2023-07-19 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2579602B2 (ja) 1992-10-21 1997-02-05 吉富製薬株式会社 2−アミノ−1,3−プロパンジオール化合物および免疫抑制剤
ECSP951461A (es) 1995-06-07 1998-04-07 SINTESIS DE 3- {4-(2- AMINOETOXI) BENZOIL]-2-ARIL-6- HIDROXIBENZO {b] TIOFENOS (CASO X- 9295B)
ECSP972265A (es) 1997-09-23 1998-11-30 Dihidrato de d-olanzapina
FR2785607B1 (fr) 1998-11-09 2001-02-09 Rhodia Chimie Sa Procede de preparation de tris(ether-amine)
PT1129066E (pt) * 1998-11-11 2005-05-31 Taito Co Producao de 2-amino-2-[2-(4-c2-20-alquil-fenil)etil]propano-1,3-diois
JP4627356B2 (ja) * 1999-06-30 2011-02-09 昭 松森 ウイルス性心筋炎の予防または治療薬剤
AU2002320828B2 (en) * 2001-06-08 2006-02-02 Novartis Ag Treatment or prophylaxis of insulin-producing cell graft rejection
MXPA04011384A (es) * 2002-05-16 2005-02-14 Novartis Ag Uso de agentes de union del receptor edg en cancer.
GB0217152D0 (en) * 2002-07-24 2002-09-04 Novartis Ag Organic compounds
CA2521325C (en) 2003-04-08 2010-09-14 Novartis Ag Solid pharmaceutical compositions comprising a s1p receptor agonist and a sugar alcohol
GT200600350A (es) 2005-08-09 2007-03-28 Formulaciones líquidas
RU2008116578A (ru) * 2005-09-30 2009-11-10 Новартис АГ (CH) Применение ингибиторов dpp-iv для лечения аутоиммунных заболеваний и отторжения трансплантата
ES2414205T3 (es) * 2006-06-02 2013-07-18 The Ohio State University Research Foundation Agentes terapéuticos para el tratamiento de linfoma de células del manto
WO2009100116A1 (en) * 2008-02-04 2009-08-13 Medical College Of Georgia Research Institute Oligodendrocyte precursor cell composition and methods of use
AU2009315735B2 (en) * 2008-11-11 2013-01-10 Novartis Ag Salts of fingolimod

Similar Documents

Publication Publication Date Title
JP2012508215A5 (cg-RX-API-DMAC10.html)
RU2011123365A (ru) Соли финголимода
RU2011123371A (ru) Кристаллические формы гидрохлорида финголимода
ES2683355T3 (es) Profármacos de fumaratos y su uso en el tratamiento de diversas enfermedades
JP2018035160A5 (cg-RX-API-DMAC10.html)
HRP20210928T1 (hr) Soli ili ko-kristali 3- (3-dimetilamino-1-etil-2-metil-propil)-fenola
ME02275B (me) Polimorfni oblik rotigotina
JP2012523395A5 (cg-RX-API-DMAC10.html)
JP2009084270A5 (cg-RX-API-DMAC10.html)
JP2018518537A5 (cg-RX-API-DMAC10.html)
JP2011510014A5 (cg-RX-API-DMAC10.html)
JP2010514831A5 (cg-RX-API-DMAC10.html)
RU2011145054A (ru) Кристаллические формы саксаглиптина
JP2015145426A5 (cg-RX-API-DMAC10.html)
JP2010514832A5 (cg-RX-API-DMAC10.html)
JP2014511892A5 (cg-RX-API-DMAC10.html)
JP2014524442A5 (cg-RX-API-DMAC10.html)
JP2010529203A5 (cg-RX-API-DMAC10.html)
JP2020510661A5 (cg-RX-API-DMAC10.html)
JP2016503010A5 (cg-RX-API-DMAC10.html)
JP2020534270A5 (cg-RX-API-DMAC10.html)
JP2014530818A5 (cg-RX-API-DMAC10.html)
JP2016539136A5 (cg-RX-API-DMAC10.html)
JP2023109937A5 (cg-RX-API-DMAC10.html)
JP2009534373A5 (cg-RX-API-DMAC10.html)